预测测试市场规模、份额、按测试类型、技术、应用、最终用户和地区分類的成长分析 - 2025 年至 2032 年产业预测

2023 年全球预测测试市场规模为 49 亿美元，预计将从 2024 年的 53.6 亿美元成长到 2032 年的 109.1 亿美元，预测期内（2025-2032 年）的复合年增长率为 9.3%。

医疗技术领域正在经历显着增长，这得益于人们对早期疾病检测的日益关注和预测工具的进步。人们对早期检测益处的认识不断提高，以及更准确、更实惠的检测方法的开发，使得这些解决方案对患者和医疗保健提供者都具有吸引力。政府和私人组织透过资金和政策倡议提供的支持将进一步加强创新和采用的环境。然而，障碍包括高成本，特别是在中低收入国家，以及对资料隐私和道德的担忧。基因组学和生物资讯学的持续创新以及对精准医疗的关注开闢了巨大的成长机会。相关人员之间的合作对于克服障碍和确保市场的长期永续性至关重要。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 生态系测绘
• 市场吸引力指数（2023年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究
• 技术分析
• 监管格局

预测测试市场规模（按测试类型和复合年增长率） (2025-2032)

• 市场概览
• 基因检测
• 生物标记检测
• 家族病史评估
• 多基因风险评分

预测测试市场规模（依技术及复合年增长率） (2025-2032)

• 市场概览
• 次世代定序
• 微阵列分析
• 桑格定序
• PCR检测

预测测试市场规模（按应用划分）及复合年增长率（2025-2032）

• 市场概览
• 肿瘤学
• 心臟病学
• 神经病学
• 罕见遗传疾病

预测测试市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 诊断实验室
• 研究机构
• 家庭检测套组

预测测试市场规模（按地区划分）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Veracyte, Inc.
• Abbott
• 23andMe, Inc.
• PharmaMar
• Quest Diagnostics Incorporated
• Celerion
• Myriad Genetics, Inc.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Genomic Health
• Caris Life Sciences
• Natera, Inc.
• F. Hoffmann-La Roche
• Exact Sciences Corporation
• BioAxis DNA Research Centre Private Limited
• Color Genomics, Inc.
• Direct Laboratory Services LLC（DirectLabs）
• Gene Ltd.
• Pathway Genomics Corporation
• Positive Bioscience, Inc.

结论和建议

Global Predictive Presymptomatic Testing market was valued at USD 4.9 Billion in 2023 and is expected to grow from USD 5.36 Billion in 2024 to USD 10.91 Billion by 2032, with a CAGR of 9.3% during the forecast period (2025-2032).

The healthcare technology sector is experiencing significant growth, fueled by rising interest in early disease detection and advancements in predictive tools. Increased awareness of the benefits of early detection, coupled with the development of more accurate and affordable testing methods, makes these solutions appealing to both patients and healthcare providers. Support from government and private organizations through funding and policy initiatives further enhances the environment for innovation and adoption. However, barriers such as high costs, especially in low- and middle-income countries, and concerns over data privacy and ethics pose challenges. Continuous innovation in genomics and bioinformatics, along with a focus on precision medicine, opens up substantial growth opportunities. Collaborative efforts among stakeholders will be crucial for overcoming hurdles and ensuring the long-term sustainability of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Predictive Presymptomatic Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Predictive Presymptomatic Testing Market Segments Analysis

The global predictive presymptomatic testing market is segmented into test type, technology, application, end user, and region. By test type, the market is classified into genetic testing, biomarker testing, family history assessment, and polygenic risk score. Depending on technology, it is divided into next-generation sequencing, microarray analysis, sanger sequencing, and PCR-based testing. According to application, the market is categorized into oncology, cardiology, neurology, and rare genetic disorders. Based on End User, the market is segmented into hospitals, diagnostic laboratories, research institutions, and home testing kits. Regionally, the market is analyzed across North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.

Driver of the Global Predictive Presymptomatic Testing Market

The increasing prevalence of chronic noncommunicable diseases (NCDs) like cancer, diabetes, and cardiovascular ailments is fueling the demand for presymptomatic predictive testing. According to the World Health Organization (WHO), NCDs account for a staggering 74% of global deaths, with a significant 86% of these preventable fatalities occurring in low- and middle-income countries. Forecasts from countries such as England and India indicate a dramatic rise in disease incidence, highlighting the critical importance of early detection in improving health outcomes and alleviating the pressures on healthcare systems. This growing urgency underscores the necessity for advanced predictive testing solutions on a global scale.

Restraints in the Global Predictive Presymptomatic Testing Market

Despite significant advancements that have driven genome sequencing costs below USD 100, the high overall expenses associated with performing next-generation sequencing (NGS) assays, ranging from USD 5,000 to USD 7,000, remain a formidable barrier. This challenge is exacerbated by limited reimbursement policies, particularly in low- and middle-income countries. The World Health Organization emphasizes the importance of equitable access to healthcare as a means to reduce disparities globally. Consequently, these financial limitations impede the widespread adoption of presymptomatic testing technologies, highlighting the urgent need for improved funding and policy support to facilitate access and drive market growth.

Market Trends of the Global Predictive Presymptomatic Testing Market

The Global Predictive Presymptomatic Testing market is experiencing a significant surge, driven by the convergence of genomics and digital health technologies. In the short term, governments and healthcare organizations prioritize the integration of genetic testing with digital platforms, enhancing patient care through precision medicine initiatives like the European Union's Horizon Europe. This investment fosters the development of digital solutions that facilitate seamless data sharing and remote monitoring, ultimately enabling personalized health coaching and disease prevention. As a result, predictive presymptomatic testing becomes increasingly convenient and accessible, catering to a growing demand for proactive health management and tailored healthcare solutions globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree Of Competition
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2023
• Pestel Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study
• Technology Analysis
• Regulatory Landscape

Global Predictive Presymptomatic Testing Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Genetic Testing
• Biomarker Testing
• Family History Assessment
• Polygenic Risk Score

Global Predictive Presymptomatic Testing Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Next-Generation Sequencing
• Microarray Analysis
• Sanger Sequencing
• PCR-Based Testing

Global Predictive Presymptomatic Testing Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology
• Cardiology
• Neurology
• Rare Genetic Disorders

Global Predictive Presymptomatic Testing Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Research Institutions
• Home Testing Kits

Global Predictive Presymptomatic Testing Market Size & CAGR (2025-2032)

• North America (Test Type, Technology, Application, End User)
  • US
  • Canada
• Europe (Test Type, Technology, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Technology, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Technology, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Technology, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Veracyte, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 23andMe, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PharmaMar
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celerion
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caris Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioAxis DNA Research Centre Private Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Color Genomics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Direct Laboratory Services LLC (DirectLabs)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gene Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pathway Genomics Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Positive Bioscience, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations